EVALUATION OF THERAPEUTIC EFFECT OF RIFAMPIN FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SABOURI M.R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: BINA Year:2013 | Volume:19 | Issue:1 (74) Page(s): 46-51

Download Full-Text

Persian Verion

View:

640

Download:

Cites:

Information Journal Paper

Title

EVALUATION OF THERAPEUTIC EFFECT OF RIFAMPIN FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY

Author(s)

SABOURI M.R. | Issue Writer Certificate

Keywords

RIFAMPINQ3

ACUTE CENTRAL SEROUS CHORIORETINOPATHYQ3

Abstract

Purpose: To evaluate the beneficial effects of RIFAMPIN for the treatment of central serous chorioretinopathy (CSCR).Methods: In this non-randomized clinical trial, 39 patients with acute CSCR (<2 weeks) were enrolled.Initially, complete visual examinations including determination of best spectacle-corrected visual acuity (BSCVA) using Snellen chart, anterior and posterior segment examination was performed. Fundus fluorescein angiography (FFA) and ocular coherence tomography (OCT) were also performed to confirm the diagnosis. Twenty-three patients were treated with 600 mg RIFAMPIN per day for a maximum of 4-6 weeks (treatment group) and 17 patients did not receive any treatment (control group). The patients were examined post treatment at weeks 2, 4 & 6. At each follow-up examination BCVA and fundoscopy were performed. If no macular edema was observed in fundOscopy, OCT was performed, otherwise OCT was performed at the end of 4th-6th week. Primary objective was reduction in macular thickness (MT) and secondary objective was the BSCVA.Results: Mean age of patients was 38.5±6.7 years, 37.7±6.2 years in the treatment group and 39.7±7.3 years in the control group (P>0.05).76.9% of patients were male. Mean MT reduced from 339.9±44.36mm at the beginning of treatment to 297.4±29.09mm at the final visit (12.58% reduction, P<0.001). In the control group, the figures were 310.06±20.31 and 296.71±17.22mm, respectively (4.3% reduction, (P<0.003). The treatment group demonstrated more reduction in MT (P<0.018). Mean BSCVA was 0.2±0.18 and 0.6±0.34 SV before and after treatment respectively (P<0.0001) in the treatment group and 0.2±0.1 and 0.37±0.35 SV, respectively (P<0.024) in the control group. The difference in BSCVA between the two groups was significant (P=0.055). Macula was dry in 45.5% of the treatment group and 29.4% of the control group at the end of study (OR=2 CI95%, 0.52-7.6, P=0.307). All the patients with dry macula at the end of study in the treatment group were followed for 9 months and no recurrence of the lesion was found.Conclusion: RIFAMPIN has beneficial effects in the treatment of acute CSCR. These early findings suggest a novel treatment of CSCR and warranted further study.

Cites

No record.

References

No record.

Cite

Related Journal Papers